Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Core Insights - Vanda Pharmaceuticals reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.14, representing an earnings surprise of 42.86% [1] - The company posted revenues of $53.19 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 4.28% and up from $45.27 million a year ago [2] - Vanda shares have underperformed the market, losing about 0.8% since the beginning of the year compared to the S&P 500's gain of 2.9% [3] Company Performance - Over the last four quarters, Vanda has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] - The current consensus EPS estimate for the coming quarter is -$0.12 on revenues of $54.25 million, and -$0.35 on revenues of $241 million for the current fiscal year [7] - The estimate revisions trend for Vanda is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Vanda belongs, is currently in the top 27% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Vanda's stock performance [5]